Skip to main content
Ian Gaudet

Ian Gaudet

Chief Scientific Director, Bioindustry, Miltenyi Bioindustry
Miltenyi Bioindustry is a global CDMO with 5 sites across the world. We support all efforts for cell therapy developers, from pre-clinical to commercial scale, as a full-service provider for the development and manufacture of cell therapy products and lentiviral vectors. We have been manufacturing clinical cell therapy products since 2017, and we are completely integrated with our cell therapy and analytical platforms. As the leading experts in our technology, we specialize in enabling automated and closed manufacturing of cutting edge autologous and allogeneic cell therapy processes. Maintaining our dedication and integration into cell therapy workflow, we have been manufacturing GMP lentiviral vector since 2014. We leverage a platform process designed to minimize time spent in PD and deliver high quality LVV in shorter timelines. Our VSV-G LVV platform can take you from preclinical through commercial manufacturing. We also recently launched our preclinical BaEV LVV platform designed for typically harder-to-transduce cell types such as NK cells (clinical platform available in 2025). We are a division of Miltenyi Biotec, a pioneering innovator in the cell therapy industry for over 30 years.